2. Academic Validation
  3. New prostaglandin derivative for glaucoma treatment

New prostaglandin derivative for glaucoma treatment

  • Bioorg Med Chem Lett. 2009 Mar 15;19(6):1639-42. doi: 10.1016/j.bmcl.2009.02.007.
Elena Perrino 1,  Caterina Uliva,  Cecilia Lanzi,  Piero Del Soldato,  Emanuela Masini,  Anna Sparatore
Affiliations

Affiliation

  • 1 Istituto di Chimica Farmaceutica e Tossicologica 'Pietro Pratesi', University of Milan, Via Mangiagalli 25, 20133 Milan, Italy.
PMID: 19233645 DOI: 10.1016/j.bmcl.2009.02.007
Abstract

A hydrogen sulphide-releasing derivative of latanoprost acid (ACS 67) was synthesized and tested in vivo to evaluate its activity on reduction of intraocular pressure and tolerability. Glutathione (GSH) and cGMP content were also measured in the aqueous humour. The increased reduction of intraocular pressure, with a marked increase of GSH and cGMP and the related potential neuroprotective properties, make this compound interesting for the treatment of glaucoma. This is the first time that an application of a hydrogen sulphide-releasing molecule is reported for the treatment of ocular diseases.

Figures
Products